PUBLICATION
Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent
- Authors
- Hanh, B.T.B., Park, J.W., Kim, T.H., Kim, J.S., Yang, C.S., Jang, K., Cui, J., Oh, D.C., Jang, J.
- ID
- ZDB-PUB-200422-15
- Date
- 2020
- Source
- Molecules 25(7): (Journal)
- Registered Authors
- Keywords
- Mycobacterium abscessus, drug resistance, non-tuberculous mycobacteria, rifamycin, zebrafish bacterial infection
- MeSH Terms
-
- Animals
- Anti-Bacterial Agents/chemistry
- Anti-Bacterial Agents/pharmacology*
- Humans
- Luminescent Measurements
- Mice
- Microbial Sensitivity Tests
- Molecular Structure
- Mycobacterium abscessus/drug effects*
- Rifamycins/chemistry
- Rifamycins/pharmacology*
- Zebrafish
- PubMed
- 32244387 Full text @ Molecules
Citation
Hanh, B.T.B., Park, J.W., Kim, T.H., Kim, J.S., Yang, C.S., Jang, K., Cui, J., Oh, D.C., Jang, J. (2020) Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent. Molecules. 25(7):.
Abstract
Mycobacterium abscessus is the most difficult-to-treat nontuberculous mycobacteria because of its resistance to many antibiotics. In this study, we screened the Korea Chemical Bank library for a bioluminescent reporter assay to identify molecules capable of acting against M. abscessus. On application of the assay, rifamycin O showed excellent in vitro activity with a narrow range of the minimum inhibitory concentration required to inhibit the growth of 90% of the bacterium (MIC90 = 4.0-6.2 μM); its in vivo efficacy in the zebrafish (Danio rerio) infection model was comparable to that of rifabutin at 25 μM. Furthermore, rifamycin O did not show significant toxicity in cells and the zebrafish model. These results are the first in vivo indication that rifamycin O may be a drug candidate for treating M. abscessus infections.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping